Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immune Reconstitution in Tuberculosis Disease (IRETB)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2012 by Karolinska Institutet
Sponsor:
Collaborators:
Addis Ababa University
Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia
Information provided by (Responsible Party):
Susanna Brighenti, Karolinska Institutet
ClinicalTrials.gov Identifier:
NCT01698476
First received: September 25, 2012
Last updated: October 2, 2012
Last verified: October 2012

September 25, 2012
October 2, 2012
September 2012
December 2015   (final data collection date for primary outcome measure)
Composite clinical TB score [ Time Frame: 0 (baseline) compared to 8 weeks. ] [ Designated as safety issue: Yes ]
A previously described composite clinical TB score will be used to monitor the efficacy of vitamin D and phenylbutyrate treatment among TB patients on standard chemotherapy. The numerical TB score will include self-reported clinical symptoms (cough, night sweats and chest pain) as well as different parameters determined upon clinical examination anemia/conjunctival pallor, haemoptysis, dyspnoea, tachycardia, positive finding at lung auscultation, fever, low body mass index (BMI) and low mid upper arm circumference (MUAC). The TB score will be determined at the time of diagnosis (time point 0) and at 4, 8, 16 and 24 weeks after initiation of antimicrobial treatment with vitamin D and phenylbutyrate. The primary endpoint will be assessed at time point 8 weeks compared to baseline (time point 0).
Same as current
Complete list of historical versions of study NCT01698476 on ClinicalTrials.gov Archive Site
  • Clinical secondary endpoints [ Time Frame: 0-4, 8, 16 and 24 weeks ] [ Designated as safety issue: Yes ]

    Clinical composite TB score (0, 4, 16, 24 weeks).

    Modified clinical composite TB score (0, 4, 8, 16, 24 weeks).

    Chest X-ray (0, 4, 8, 16, 24 weeks).

    Time to sputum- and/or TB culture conversion (0, 1, 2, 3, 4, 8 weeks).

  • Laboratory secondary endpoints [ Time Frame: 0, 4, 8, 16, 24 weeks ] [ Designated as safety issue: No ]

    Peripheral CD4/CD8 T cell counts.

    Antibodies in lymphocytes secertions (ALS) (S Ashenafi, Thorax, 2012).

    Quantiferon-in-tube TB-gold (QFT).

    Plasma levels of vitamin D, LL-37 and also cytokine/chemokine profiles.

    Functional studies of immune cells (PBMCs).

Same as current
Interim analysis [ Designated as safety issue: Yes ]
An interim analysis will be performed after approx. 100-150 patients have been included into the study.
Same as current
 
Immune Reconstitution in Tuberculosis Disease
Immune Reconstitution in Tuberculosis Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate

The aim with study is to provide adjunctive therapy with vitamin D and phenylbutyrate together with standard anti-tuberculosis treatment to significantly improve clinical recovery among patients with untreated, active pulmonary tuberculosis.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Pulmonary Tuberculosis (TB)
  • Drug: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
    Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
  • Drug: Placebo tablets
  • Active Comparator: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
    Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
    Intervention: Drug: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
  • Placebo Comparator: Placebo tablets
    Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
    Intervention: Drug: Placebo tablets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
December 2016
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

HIV negative patients, adult patients >18 years who has not started anti-TB therapy.

Newly diagnosed pulmonary TB confirmed by microscopy or culture but also sputum-negative clinical TB cases (defined according to the WHO 2006 criteria for sputum smear-negative TB ie. clinical symptoms of TB, chest X-ray findings and response to standard treatment).

Exclusion Criteria:

Patients who have already started treatment with anti-TB drugs for more that 5 days.

HIV-positive patients.

History of anti-TB treatment in the past 2 years.

Local extra-pulmonary TB in the absence of lung manifestations.

Hypercalcaemia (serum calcium > 2.6 mmol/L) identified at baseline.

Pregnant and breast feeding women.

Any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.

Both
18 Years to 75 Years
No
Contact: Endale Kassa, MD 251-911228562 endalekassalulu@gmail.com
Contact: Wondwossen Amogne, MD 251-911406179 wonamogne@yahoo.com
Ethiopia
 
NCT01698476
IRETB-2012
Yes
Susanna Brighenti, Karolinska Institutet
Karolinska Institutet
  • Addis Ababa University
  • Armauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia
Principal Investigator: Susanna Brighenti, PhD Karolinska Institutet
Karolinska Institutet
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP